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Glibenclamide Unresponsiveness in a Brazilian Child with 
Permanent Neonatal Diabetes Mellitus and DEND Syndrome 
Due to a C166Y Mutation in KCNJ11 (Kir6.2) Gene
ABSTRACT
Heterozygous activating mutations of KCNJ11 (Kir6.2) are the most common 
cause of permanent neonatal diabetes mellitus (PNDM) and several cases have 
been successfully treated with oral sulfonylureas. We report on the attempted 
transfer of insulin therapy to glibenclamide in a 4-year old child with PNDM and 
DEND syndrome, bearing a C166Y mutation in KCNJ11. An inpatient transition 
from subcutaneous NPH insulin (0.2 units/kg/d) to oral glibenclamide (1 mg/
kg/d and 1.5 mg/kg/d) was performed. Glucose and  C-peptide responses stimu-
lated by oral glucose tolerance test (OGTT), hemoglobin A1c levels, the 8-point 
self-measured blood glucose (SMBG) profi le and the frequency of hypoglyce-
mia episodes were analyzed, before and during treatment with glibenclamide. 
Neither diabetes control nor neurological improvements were observed. We 
concluded that C166Y mutation was associated with a form of PNDM insensi-
tive to glibenclamide. (Arq Bras Endocrinol Metab 2008; 52/8:1350-1355)
Keywords: Neonatal diabetes mellitus; KATP channels; KCNJ11; C166Y muta-
tion; Glibenclamide; Treatment failure 
RESUMO
Falha de resposta à Glibenclamida em Criança Brasileira com Diabetes Melito 
Neonatal Permanente e Síndrome DEND Devido a Mutação C166Y no Gene 
KCNJ11 (Kir6.2).
As mutações ativadoras, heterozigóticas do gene KCNJ11 (Kir6.2) são a causa 
mais freqüente de diabetes melito neonatal permanente (DMNP) e a terapêu-
tica oral com sulfoniluréias tem sido bem sucedida em muitos destes casos. 
Relatamos o processo de substituição da insulinoterapia convencional para o 
tratamento oral com glibenclamida em uma paciente de 4 anos, portadora de 
DMNP e síndrome DEND devido a uma mutação C166Y no gene KCNJ11. A 
insulina NPH (0,2 U/kg/dia) foi substituída pela glibenclamida (1 mg/kg/dia e 
1,5 mg/kg/dia) durante internação hospitalar. As respostas de glicose e pep-
tídeo-C no teste de tolerância oral à glicose (OGTT), os níveis de hemoglobina 
glicada, o perfi l de glicemias capilares de 8 pontos e a freqüência de hipogli-
cemias foram comparados antes e durante o tratamento com glibenclamida. 
Não houve melhora no controle glicêmico, nem no quadro neurológico. Con-
cluímos que a mutação C166Y associa-se a uma forma de DMNP insensível à 
glibenclamida. (Arq Bras Endocrinol Metab 2008; 52/8:1350-1355)
Descritores: Diabetes melito neonatal; Canais KATP; KCNJ11; Mutação C166Y; 
Glibenclamida; Falha de tratamento
INTRODUCTION
Neonatal diabetes mellitus (NDM) is a rare condition with an estimated incidence of 1:300.000 to 1:500.000 live births (1-4), defi ned as persis-
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She was doing well until 3 months old when she ma-
nifested an exaggerated crying with irritability, and one 
month later she exhibited repeated head and limbs spasms 
followed by drowsiness. After physical and neurological 
examination, failure to thrive, muscle weakness, hypoto-
nia and development delay were evident. A subsequent 
electroencephalogram showed slow background activity 
with multifocal spikes and slow wave complexes and then 
she was initiated on valproic acid (40 mg/kg/d).
At the age of 5 months she developed fever, polyu-
ria, irritability and laboratory work-up revealed gluco-
suria and a blood glucose level of 900 mg/dL; however, 
ketoacidosis was not documented. She received intra-
venous normal saline and was started on subcutaneous 
insulin therapy with NPH human insulin and fast-ac-
ting insulin analogue (lispro) to correct hyperglycemia. 
Six days later she was discharged home in use of NPH 
1.5 IU in the morning and 1 IU at bedtime, clobazam 
(10 mg/d) and valproic acid (56 mg/kg/d).
The child was referred to our outpatient clinic at 
13 months of age when she was not able to sit, speak 
syllables, or follow movements with eyes; her body wei-
ght was 8.000 g (-1.89 SDS), height was 71.5 cm 
(-1.88 SDS) and head circumference was 42.5 cm 
(-2.58 SDS). Anti-insulin and islet cell antibodies were 
negative. 
At the age of 4 she presented failure to thrive (Wei-
ght= -3.3 SDS; Height= -4.2 SDS), microcephaly, severe 
development delay, muscle weakness, epilepsy, diabetes 
mellitus (Figure 1) and was classifi ed as full DEND syn-
drome (18). A novel C166Y mutation in KCNJ11 was 
found by sequencing of the patient’s KCNJ11 gene 
using genomic DNA extracted from peripheral lym-
phocytes by standard methods (19). 
Parents were informed of the possible glibenclami-
de-related side effects and written informed consent 
was obtained before study initiation and after approval 
by local ethics committee. An inpatient transition from 
subcutaneous human NPH insulin therapy (0.2 units/
kg/d) to oral glibenclamide (1 mg/kg/d) was perfor-
med during a 4-week period followed by a washout 
phase with subcutaneous NPH insulin and a subse-
quent 4-week trial with a higher oral glibenclamide 
dose (1.5 mg/kg/d) (12). The primary outcome was 
insulin independence after a 4-week period on gliben-
clamide, with a maximum dose of 1.5 mg/kg/d. Cor-
rection bolus doses with fast-acting insulin analogue 
(lispro) were done every time blood glucose levels were 
≥ 200 mg/dL.
tent hyperglycemia occurring within the fi rst 6 months of 
life, lasting more than 2 weeks and requiring insulin the-
rapy (5), and accordingly to the subsequent clinical cour-
se, it will be classifi ed as permanent or transient (1). 
Transient neonatal diabetes mellitus (TNDM) com-
prises approximately 50% of the cases and usually resolves 
in the fi rst 18 months of life although requiring insulin 
therapy until resolution (2,4,5); approximately one fourth 
of such cases will relapse from 7 to 20 years later (5).
Heterozygous activating mutations of KCNJ11 
and ABCC8 are responsible for approximately 50% of 
permanent NDM (PNDM) (6-9). Defects in several 
other genes (IPF1, GCK, HNF1B, INS, FOXP3, EI-
F2AK3) have also been implicated in PNDM (4,9), ho-
wever the activating mutations of KCNJ11, which 
reduce the ability for ATP to close the ATP-sensitive 
potassium channel (K+ATP), are the most common (6).
Glucose-stimulated insulin secretion is regulated 
by the closing of K+ATP channel which is an octameric 
complex of four pore-forming, inwardly rectifying po-
tassium-channel subunits (Kir6.2) encoded by KCNJ11 
gene and four regulatory sulfonylurea-receptor subu-
nits (SUR1) encoded by ABCC8 gene (10,11). 
Sulfonylureas have affi nity to SUR1 and stimulate 
insulin secretion by an ATP-independent mechanism 
and can successfully replace insulin therapy to achieve a 
better metabolic control in several PNDM cases due to 
KCNJ11 mutations (6,12). So the identifi cation of a 
KCNJ11 mutation has implications for clinical manage-
ment since many patients have been treated successfully 
with oral sulphonylureas rather than insulin (12-17). 
Here we describe a case of a Brazilian child with 
PNDM and DEND syndrome (Developmental Delay, 
Epilepsy, Neonatal Diabetes) (18) due to a C166Y mu-
tation in KCNJ11 gene and the results of the attemp-
ted transfer from insulin therapy to oral glibenclamide.
SUBJECTS AND METHODS
A Brazilian female child was born at 38 wk of gestation 
to a gravida 1 para 1 mother, whose pregnancy was 
uncomplicated, with a birth weight of 3000 g, length 
of 48 cm and Apgar score: 8 and 9. Her healthy parents 
were unrelated and the family history was remarkable 
for maternal grandparents with adult-onset diabetes 
and an aunt with diabetes and epilepsy. The postnatal 
course was uncomplicated and she was discharged 
home in the third day of life.
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Glucose and C-peptide stimulated by 2-hour oral 
glucose tolerance test (OGTT, 1.75 g/kg, standard 
method) were compared immediately before and after 
transition to oral glibenclamide (1 mg/kg/d). Hemo-
globin A1c levels (HPLC, Bio-Rad Laboratories, Her-
cules, CA, USA), the 8-point self-measured blood 
glucose (SMBG) profi le and the frequency of hypo-
glycemia episodes registered in Camit-Pro software for 
Accu-chek® glucometers were compared before and 
during treatment with glibenclamide (1 mg/kg/d), 
during subcutaneous NPH insulin washout phase and 
during reintroduction of a higher dose of glibenclami-
de (1.5 mg/kg/d). Data were expressed as mean ± SD; 
differences between groups were assessed by Student’s 
t-test and ANOVA, p<0.05 was considered signifi cant.
Stimulated mean blood glucose level was signifi -
cantly higher during glibenclamide (1 mg/kg/d) treat-
ment than with NPH insulin therapy (250 ± 80 vs 160 
± 54 mg/dL; p<0.01) and no difference between sti-
mulated mean plasma C-peptide (0.46 ± 0.20 vs 0.26 ± 
0.22 ng/mL) response was observed during oral gli-
benclamide and NPH insulin therapy, respectively (Fi-
gure 2). Another OGTT with oral glibenclamide (1.5 
mg/kg/d) was not performed.
Neither hemoglobin A1c levels, nor the 8-point 
SMBG profi le and frequency of hypoglycemic events 
were different during oral glibenclamide (1 and 1.5 
mg/kg/d) and NPH insulin therapy, respectively (Fi-
gures 3, 4 and 5). No side effects related to glibencla-
mide or neurological improvement were observed; 
however correction boluses of lispro insulin were re-
quired once to four times a day during glibenclamide 
treatment.
Since insulin independence was not achieved, the 
child returned on NPH and lispro insulin therapy and 
now is maintaining an adequate metabolic control.
DISCUSSION
The effectiveness of oral sulfonylurea in improving 
glycemic control of diabetic patients due to KCNJ11 
mutations after transfer from insulin therapy has been 
confi rmed by many reports, with doses ranging from 
0.05 to 1.5 mg/kg/d (12-17); however data concer-
ning the use of sulfonylurea in the treatment of PNDM 
with DEND syndrome have shown variable results. Se-
veral mutations related to severe DEND syndrome 
(Q52R, G53R, V59G, I296L, G334D) are insensitive 
to glibenclamide (4,12,19,20); nevertheless in some 
forms of intermediate DEND syndrome (I167L, 
G53D, H46L, V59M), characterized by less severe de-
velopmental delay and without epilepsy, glibenclamide 
therapy has improved metabolic control, neuromuscu-
lar symptoms (17,21-24) and even cognition (V59M) 
(25). Evidence that sulfonylurea could change CNS 
blood fl ow and function was provided by the use of 
Figure 1. Four-year old child with DEND syndrome due to a C166Y mutation in KCNJ11 (Kir6.2). Note severe development delay, 
limb spasticity and failure to thrive.
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Figure 2. Comparison of OGTT-stimulated glucose and plasma C-peptide responses during NPH insulin therapy (0.2 units/kg/d) 
and glibenclamide (GCD) (1 mg/kg/d). (Student t test).
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Figure 3. Comparison of HbA1c during NPH insulin therapy and oral glibenclamide (GCD) 1mg/kg/d and 1.5 mg/kg/d. (ANOVA).
Figure 4. Comparison of OGTT-stimulated glucose and plasma C-peptide responses during NPH insulin therapy (0.2 units/kg/d) 
and glibenclamide (GCD) (1 mg/kg/d). (Student t test).
Figure 5. Comparison of hypoglycemia frequency during NPH insulin therapy and oral glibenclamide (GCD) 1mg/kg/d and 1.5 
mg/kg/d. (ANOVA).
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single-photon emission CT (SPECT) imaging, before 
and after glibenclamide therapy (24).
The fi rst patient described with a mutation at co-
don 166 with substitution of cysteine by phenylalanine 
(C166F) presented with neonatal diabetes, full DEND 
syndrome and dysmorphic features including promi-
nent metopic suture, bilateral ptosis and down turned 
mouth, but she died from aspiration pneumonia at the 
age of 6 months after partial and transitory control of 
epilepsy with tolbutamide (0.75 mg/kg/d) combined 
with ACTH therapy (26,27). Afterwards, Flanagan et 
al. (19) demonstrated the C166Y mutation (substitu-
tion of cysteine by tyrosine) in our patient, followed by 
another case (C166Y) described by Suzuki et al. (28) of 
neonatal diabetes with DEND syndrome, dysmorphic 
facial features and arthrogryposis who has been treated 
exclusively with insulin.
Kir6.2 is expressed in several tissues including 
pancreatic β-cell, brain, heart and skeletal muscle; 
Kir6.2 mutations associated with DEND syndrome 
are believed to be less sensitive to ATP than those that 
cause isolated diabetes, and functional studies suppor-
ted a relationship between the site of the mutation 
and the ability of the channel to close in the presence 
of ATP (19,29). 
The underlying molecular mechanism on the re-
duction of ATP sensitivity varies accordingly to the site 
of Kir6.2 mutations, which can be located in the ATP-
binding site or in regions involved in channel gating. 
Some mutations may infl uence both ATP binding and 
gating, as well as the mechanism of signal transduction 
to channel closure (29,30). In this regard, Trapp and 
cols. (31) demonstrated experimentally that mutations 
at residue 166 that replace cysteine – an hydrophobic 
amino acid, by larger and less hydrophobic amino acids 
increased the channel open probability, suggesting that 
the altered intrinsic gating kinetics should be the pri-
mary channel defect in these cases, what would explain 
the unresponsiveness to sulfonylurea therapy. Phenyla-
lanine has a similar hydrophobicity to cysteine but is 
much larger, causing an increase in the channel open 
probability (31), and tyrosine is both larger and less 
hydrophobic than cysteine.
On the other hand, less severe phenotypes have 
been associated with mutations that cause defects in ei-
ther ATP binding or gating (30). Thus, clinical pheno-
type will be determined mainly by the degree of channel 
activation rather than the gene involved (4). 
In conclusion, we have demonstrated that a child 
with permanent neonatal diabetes mellitus and DEND 
syndrome due to a C166Y mutation in KCNJ11 gene 
was insensitive to glibenclamide. This lack of clinical 
response was observed both for diabetes control and 
neurological features. 
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